首页> 外文期刊>Antimicrobial agents and chemotherapy. >Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
【24h】

Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).

机译:在美国,从复杂腹腔内感染患者中分离出的革兰氏阴性病原体的敏感性,2007-2008年:监测抗菌素耐药性趋势研究(SMART)的结果。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

During 2007-2008, 1,036 gram-negative bacilli were isolated from patients with complicated intra-abdominal infections in the United States. Against members of the family Enterobacteriaceae, the most active agents in vitro were ertapenem, imipenem, and amikacin, while the least active agent was ampicillin-sulbactam. Ertapenem and imipenem were active against all extended-spectrum-beta-lactamase (ESBL)-positive Escherichia coli. Antimicrobial resistance in gram-negative bacilli isolated from patients with complicated intra-abdominal infections in the United States continues to increase.
机译:在2007-2008年期间,在美国从复杂的腹腔内感染患者中分离出1,036克阴性杆菌。针对肠杆菌科成员,体外活性最高的药物是厄他培南,亚胺培南和丁胺卡那霉素,而活性最低的药物是氨苄西林舒巴坦。厄他培南和亚胺培南对所有广谱β-内酰胺酶(ESBL)阳性大肠杆菌均具有活性。在美国,从患有复杂腹腔内感染的患者中分离出的革兰氏阴性杆菌的抗菌素耐药性持续增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号